Search

A recording of the Retina UK Professionals' Conference on 27 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.

• Conference
• Audio
• Video

James, who lives with retinitis pigmentosa, is running the TCS London Marathon in April 2025 to raise vital funds for Retina UK.

• Case study - community
• Written

This edition of Look Forward includes the very latest news about an experimental therapy by Retina UK funded researchers, an article about one of our PhD students, a calendar of events in 2025, the usual research news round-up and lots more. Please take the time to complete our Sight Loss Survey, enclosed with this edition. You can find out more about the Survey.

• Look Forward
• Audio
• Written

Cataracts and macular oedema are both associated with inherited sight loss and may respond to treatment.

A research project funded by Retina UK helped pave the way to a new gene therapy that has recently produced encouraging results in two young people with achromatopsia, a condition that causes complete colour-blindness and poor overall vision from birth.

• News
• Achromatopsia

X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.

Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.

• News
• Retinitis pigmentosa

It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.

• News
• Choroideremia
• Retinitis pigmentosa

Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.

• News
• Retinitis pigmentosa